Key result
Adding undetectable hs-cTnT to clinical scores improves one-year risk stratification in early chest pain presenters.
Why the study?
Undetectable hs-cTn upon admission may rule out acute coronary syndrome, but the value of combining undetectable hs-cTnT with clinical risk scores for one-year outcomes in patients with normal hs-cTnT required investigation.
Does undetectable hs-cTnT combined with clinical risk scores improve risk stratification for one-year outcomes in patients with chest pain and normal hs-cTnT upon admission?
Observational (n=1,593)
Does undetectable hs-cTnT combined with clinical risk scores improve risk stratification for one-year outcomes in patients with chest pain and normal hs-cTnT upon admission?
p-value: p=0.02
Clinical risk scores provide valuable additional prognostic information to undetectable hs-cTnT for one-year risk stratification in early presenters with chest pain.
May aid one-year risk stratification in early presenters; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Undetectable high-sensitivity cardiac troponin (hs-cTn) in a single determination upon admission may rule out acute coronary syndrome. We investigated undetectable hs-cTnT (<detection limit; <5 ng/l) together with clinical risk scores (GRACE, TIMI, HEART and a previously published simple score), for one-year outcomes in patients with chest pain and normal hs-cTnT (<99th percentile; <14 ng/l) upon admission. METHODS: = 1593) presenters were separately considered. RESULTS: = 0.02) further improved the model and significantly reclassified patient risk, in early presenters. The results were similar for the secondary endpoint. The TIMI risk score performed worse and the GRACE score did not give additional information. In late presenters, no clinical score provided significant additional information over hs-cTnT. CONCLUSIONS: Diagnostic algorithms should consider not only whether hs-cTnT is above or below the detection limit but also its concentration if above, for risk stratification over one year in patients with initial normal hs-cTnT. The clinical scores provide valuable additional information in early presenters.
No takes yet. Share an insight, caveat, or question.
Sanchís et al. (2020) conducted an observational in Chest pain with normal hs-cTnT (n=1,593). Undetectable hs-cTnT and clinical risk scores was evaluated on One-year outcomes (p=0.02). Combining undetectable hs-cTnT with clinical risk scores significantly improved risk stratification over one year in early presenters with chest pain and normal initial hs-cTnT (P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: